Veligrotug

From EyeWiki

All content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.

Assigned editor:
Review:
Assigned status Update Pending
.


Background

FDA-Approved Indication

Administration and Dosing

Adverse Effects and Contraindications

Clinical Evidence in Thyroid Eye Disease

Summary of Current Evidence

Comparison to Existing and Emerging TED Therapies

Teprotumumab

Off-label Agents

Emerging IGF-1R/TSHR-Pathway Agents

References

The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.